1 / 39

Current anti- anginal therapy

Current anti- anginal therapy. TMR. EECP. Chelation therapy. Exercise training. SCS. Fasudil. Nicorandil. Trimetazidine. Ivabradine. Ranolazine. Current antianginal strategies. Non pharmacologic. Current anti-anginal strategies. Pharmacologic. Exercise Training

devaki
Télécharger la présentation

Current anti- anginal therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Current anti-anginal therapy

  2. TMR EECP Chelation therapy Exercise training SCS Fasudil Nicorandil Trimetazidine Ivabradine Ranolazine Current antianginal strategies Non pharmacologic Current anti-anginal strategies Pharmacologic

  3. Exercise Training Enhanced external counterpulsation (EECP)  Endothelial function Promotes coronary collateral formation  Peripheral vascular resistance  Ventricular function Placebo effect Chelation therapy Transmyocardial revascularization (TMR) Sympathetic denervation Angiogenesis Spinal cord stimulation (SCS)  Neurotransmission of painful stimuli  Release of endogenous opiates Redistributes myocardial blood flow to ischemic areas Current nonpharmacologic antianginal strategies Allen KB et al. N Engl J Med. 1999;341:1029-36. Bonetti PO et al. J Am Coll Cardiol. 2003;41:1918-25.Murray S et al. Heart. 2000;83:217-20.

  4. Potential cardioprotective benefits of exercise NO production ROS generation ROS scavenging Other mechanisms Vasculature Myocardium Thrombosis Domenech R. Circulation. 2006;113:e1-3. Kojda G et al. Cardiovasc Res. 2005;67:187-97. Shephard RJ et al. Circulation. 1999;99:963-72.

  5. EECP - Enhanced External CounterPulsation • External, pneumatic compression of lower extremities in diastole.

  6. EECP - Enhanced External CounterPulsation

  7. Sequential inflation of cuffs Retrograde aortic pressure wave Increased Coronary perfusion pressure Increased Venous Return Increased Preload Increased Cardiac Output EECP - Enhanced External CounterPulsation Simultaneous deflation of cuffs in late Diastole • Lowers Systemic Vascular Resistance • Reduced Preload • Decreased Cardiac workload • Decreased Oxygen Consumption

  8. EECP - Enhanced External CounterPulsation • 35 total treatments • 5 days per week x 7 weeks • 1 hour per day • Appears to reduce severity of Angina • Not shown to improve survival or reduce myocardial infarctions • Indicated for CAD not amenable to revascularization • Anatomy not amenable to procedures • High risk co-morbidities with excessive risk • May be beneficial in treatment of refractory CHF too, but generally this is not an approved indication.

  9. EECP – Contraindications & Precautions • Arrhythmias that interfere with machine triggering • Bleeding diathesis • Active thrombophlebitis & severe lower extremity vaso-occlusive disease • Presence of significant AAA • Pregnancy

  10. TMLR - Transmyocardial Laser Revascularization • High power CO2 YAG and excimer laser conduits in myocardial to create new channels for blood flow • Possible explanations for effect • Myocardial angiogenesis • Myocardial denervation • Myocardial fibrosis with secondary favorable remodeling

  11. TMLR – Direct Trial • Only major blinded study • 298 pts with low dose, high dose, or no laser channels • No benefit to TMLR vs Med therapy to • Patient survival • Angina class • Quality of life assessment • Exercise duration • Nuclear perfusion imaging • Leon MB, et al. JACC 2005; 46:1812 • High Surgical Risk (Mortality 5%) • Mainly used as adjunct therapy during CABG to treat myocardial that cannot be bypassed.

  12. Chelation Therapy • IV EDTA infusions • 30 treatments over about 3 months • Cost – about $3,000 • Aggressive marketing by 500 to 1000 physicians offering this treatment • PLACEBO effect only • Claimed pathophysiologic effects • Liberation of Calcium in plaque • Lower LDL, VLDL, and Iron stores • Inhibit platelet aggregation • Relax vasomotor tone • Scavenge “free radicals”

  13. power source conducting wires electrodes at stimulation site Spinal Cord Stimulation Stimulation typically administered for 1-2 hrs tid Therapeutic mechanism appears to be alteration of anginal pain perception

  14. Long-term Outcomes Following SCS Prospective Italian Registry: 104 Patients, Follow-up 13.2 Mo * p<0.0001 * * * * * * * Episodes/wk (DiPede, et al. AJC 2003;91:951)

  15. Randomized Trial of SCS vs. CABG For Patients with Refractory Angina 104 Patients with refractory angina, not suitable for PCI and high risk for re-op (3.2% of patients accepted for CABG) * * * * *P < 0.0001 Spinal cord stimulation (n=53) CABG (n=51) No difference in symptom relief between SCS and CABG (Mannheimer, et al. Circulation 1998;97:1157)

  16. Current pharmacologic antianginal strategies • New mechanistic approaches to angina • Rho kinase inhibition (fasudil) • Metabolic modulation (trimetazidine) • Preconditioning (nicorandil) • Sinus node inhibition (ivabradine) • Late Na+ current inhibition (ranolazine)

  17. Rho Fasudil Rho kinase Rho kinase inhibition: Fasudil • Rho kinase triggers vasoconstriction through accumulation of phosphorylated myosin Agonist Ca2+ Ca2+ Receptor PLC PIP2 VOC ROC IP3 SR Ca2+ Myosin Myosin phosphatase MLCK Ca2+ Myosin-P Calmodulin Adapted from Seasholtz TM. Am J Physiol Cell Physiol. 2003;284:C596-8.

  18. Trimetazidine Metabolic modulation (pFOX): Trimetazidine • O2 requirement of glucose pathway is lower than FFA pathway • During ischemia, oxidized FFA levels rise, blunting the glucose pathway Myocytes Glucose FFA Acyl-CoA Pyruvate β-oxidation Acetyl-CoA Energy for contraction pFOX = partial fatty acid oxidation FFA = free fatty acid MacInnes A et al. Circ Res. 2003;93:e26-32. Lopaschuk GD et al. Circ Res. 2003;93:e33-7. Stanley WC. J Cardiovasc Pharmacol Ther. 2004;9(suppl 1):S31-45.

  19. Preconditioning: Nicorandil • Activation of ATP-sensitive K+ channels • Ischemic preconditioning • Dilation of coronary resistance arterioles O N HN NO2 O • Nitrate-associated effects • Vasodilation of coronary epicardial arteries IONA Study Group. Lancet. 2002;359:1269-75. Rahman N et al. AAPS J. 2004;6:e34.

  20. Sinus node inhibition: Ivabradine SA = sinoatrial DiFrancesco D. Curr Med Res Opin. 2005;21:1115-22.

  21. Sinus node inhibition: Ivabradine SA node AV node Common bundle Bundle branches Purkinje fibers SA = sinoatrial DiFrancesco D. Curr Med Res Opin. 2005;21:1115-22.

  22. Sinus node inhibition: Ivabradine • If current is an inward Na+/K+ current that activates pacemaker cells of the SA node • Ivabradine • Selectively blocks If in a current-dependent fashion • Reduces slope of diastolic depolarization, slowing HR Control Ivabradine 0.3 µM 40 20 Time (seconds) 0 0.5 –20 –40 –60 Potential (mV) SA = sinoatrial DiFrancesco D. Curr Med Res Opin. 2005;21:1115-22.

  23. 0 0 SodiumCurrent Late SodiumCurrent Late Peak Peak Myocardial ischemia causes enhanced late INa Ischemia Na+ Impaired Inactivation Na+ Adapted from Belardinelli L et al. Eur Heart J Suppl. 2006;(8 suppl A):A10-13. Belardinelli L et al. Eur Heart J Suppl. 2004;6(suppl I):I3-7.

  24. Ranolazine Late Na+ current inhibition: Ranolazine Myocardial ischemia Late INa Na+ Overload Ca2+ Overload Mechanical dysfunctionLV diastolic tensionContractility Electrical dysfunctionArrhythmias Belardinelli L et al. Eur Heart J Suppl. 2006;8(suppl A):A10-13.Belardinelli L et al. Eur Heart J Suppl. 2004;(6 suppl I):I3-7.

  25. Ranolazine Understanding Angina at the Cellular Level • Ischemia impairs cardiomyocyte sodium channel function • Impaired sodium channel function leads to: • Pathologic increased late sodium current • Sodium overload • Sodium-induced calcium overload • Calcium overload causes diastolic relaxation failure, which: • Increases myocardial oxygen consumption • Reduces myocardial blood flow and oxygen supply • Worsens ischemia and angina Ischemia ↑ Late INa Na+ Overload Ca++ Overload Diastolic relaxation failure Extravascular compression Chaitman BR. Circulation. 2006;113:2462-2472

  26. Na+/Ca2+ overload and ischemia Myocardial ischemia Intramural small vessel compression( O2 supply) O2 demand Late Na+ current Na+ overload Diastolic wall tension (stiffness) Ca2+ overload Adapted from Belardinelli L et al. Eur Heart J Suppl. 2006;8(suppl A):A10-13.

  27. Ranolazine Ischaemia ( oxygen supply/ Demand)  Vascular compression •  late Na+ current • Na+/Ca++ exchange pump activation  Diastolic wall tension (stiffness)  [Na+]i [Ca2+] overload

  28. Ranolazine – hemodynamic affects • No affect of Blood Pressure or Heart Rate • Can be added to Conventional Medical therapy, especially when BP and HR do not allow further increase in dose of BetaBlockers, Ca Channel blockers, and Long Acting Nitrates. • Ranolazine has twin pronged action. • pFOX • Late Na inward entry blockade

  29. Metabolic modulation (pFOX) and ranolazine • Clinical trials showed ranolazine SR 500–1000 mg bid (~2–6 µmol/L) reduced angina • Experimental studies demonstrated that ranolazine 100 µmol/L achieved only 12% pFOX inhibition • Ranolazine does not inhibit pFOX substantially at clinically relevant doses • Fatty acid oxidation Inhibition is not a major antianginal mechanism for ranolazine MacInnes A et al. Circ Res. 2003;93:e26-32. Antzelevitch C et al. J Cardiovasc Pharmacol Therapeut. 2004;9(suppl 1):S65-83.Antzelevitch C et al. Circulation. 2004;110:904-10. pFOX = partial fatty acid oxidation

  30. Ranolazine: Key concepts • Ischemia is associated with ↑ Na+ entry into cardiac cells • Na+ efflux by Na+/Ca2+ exchange results in ↑ cellular [Ca2+]i and eventual Ca2+ overload • Ca2+ overload may cause electrical and mechanical dysfunction • ↑ Late INa is an important contributor to the [Na+]i - dependent Ca2+ overload • Ranolazine reduces late INa Belardinelli L et al. Eur Heart J Suppl. 2006;8(suppl A):A10-13.Belardinelli L et al. Eur Heart J Suppl. 2004;(6 suppl I):I3-7.

  31. Ischemia Reperfusion 90 60 30 0 12 8 4 0 0 10 20 30 40 50 60 Na+ and Ca2+ during ischemia and reperfusion Rat heart model Intracellular levels Na+ (μmol/g dry) Ca2+ (μmol/g dry) Time (minutes) Tani M and Neely JR. Circ Res. 1989;65:1045-56.

  32. Pharmacologic Classes for Treatment of Angina

  33. 10 20 30 40 50 Late Na+ accumulation causes LV dysfunction Isolated rat hearts treated with ATX-II, an enhancer of late INa 6 LV+dP/dt 5 (+) Ranolazine 8.6 µM(n = 6) 4 3 LV dP/dt(mm Hg/sec, in thousands) 2 Ranolazine ATX-II 12 nM(n = 13) ATX-II 1 0 -1 -2 LV-dP/dt (-) -3 -4 Time (minutes) Fraser H et al. Eur Heart J. 2006.

  34. Late INa blockade - blunts experimental ischemic LV damage Isolated rabbit hearts LV -dP/dt (Relaxation) LV end diastolic pressure Baseline 30 60 75 90 70 0 60 -200 * 50 40 -400 mm Hg mm Hg/sec 30 * * -600 20 -800 * 10 * * -1000 0 Baseline 15 30 45 60 Reperfusion time (minutes) Reperfusion time (minutes) Vehicle (n = 12) Vehicle (n = 10) Ranolazine 5.4 µM (n = 9) Ranolazine 10 µM (n = 7) Vehicle Ranolazine *P < 0.05 Belardinelli L et al. Eur Heart J Suppl. 2004;6(suppl I):I3-7. Gralinski MR et al. Cardiovasc Res. 1994;28:1231-7.

  35. Development of ischemia Consequences of ischemia Ischemia Ranolazine Myocardial ischemia: Sites of action of anti-ischemic medication ↑ O2 Demand Heart rate Blood pressure Preload Contractility ↓ O2 Supply Ca2+ overload Electrical instability Myocardial dysfunction(↓systolic function/ ↑diastolic stiffness) Traditional anti-ischemic medications: β-blockers Nitrates Ca2+ blockers Courtesy of PH Stone, MD and BR Chaitman, MD. 2006.

  36. Summary • Ischemic heart disease is a prevalent clinical condition • Improved understanding of ischemia has prompted new therapeutic approaches • Rho kinase inhibition • Metabolic modulation • Preconditioning • Inhibition of If and late INa currents

  37. Summary • Late INa inhibition and metabolic modulation reduce angina with minimal or no pathophysiologic effects • Mechanisms of action is complementary to traditional agents

  38. Stable CAD: Multiple treatment options Lifestyle intervention Medicaltherapy Reduce symptomsTreat underlying disease Alternative TX PCI & CABG

  39. ECG R mV + T P U - Q S Wave P T QRS Space PQ ST

More Related